EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.
Overview & Synopsis
Open access biomedical research article published in Gut.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection. |
|---|---|
| Author / Organization | Tang S, Huang T, Tang R, Lin K, Luo C, Shen Y, Zhang K, Tang Y, Kong J, Chen Z, Fu J, Lin Q, Guo L, Wu Y, Li Y, Zhang J, Sun Z, You P, Zhang D, Chen Y, Lin X, Zhong C, Lin Z, Liu H, Huang Z, Zhou W, Dong P, Liu X, Zeng H, Qi X, Zeng Y |
| Subject & Discipline | Gut |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-46382 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |